STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announced its results for the second quarter 2016. Revenue for the quarter totalled SEK 1,469 M (764), an increase of 92 per cent compared to previous year. All parts of the business contributed to the result with Haemophilia, Inflammation and Partner Products delivering strong performance.
